UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells

Figure 3

UBE2C upregulates the expression of ZEB1/2 in DDP-resistant NSCLC cells. (a–c) Overexpression and knockdown of UBE2C (a), ZEB1 (b), and ZEB2 (c) were examined by RT-PCR, Western blot, and qPCR in the A549/DDP cells. (d–g) RT-PCR, Western blot, qPCR, and immunofluorescence staining assay demonstrating that knockdown or overexpression of UBE2C using siRNA and pcDNA3.1-UBE2C could decrease or increase the ZEB1in the A549/DDP cells (d, f) and ZEB2 (e, g) expression in A549/DDP cells. (i, j) RT-PCR and Western blot result show that UBE2C dose-and time-dependently increased the mRNA and protein level of ZEB1 and ZEB2 in the A549/DDP cells. (h) The transcriptional activity of ZEB1/2 regulated by UBE2C was analyzed by luciferase reporter assay. Results were presented as mean ± SD, and the error bars represent the SD of three independent experiments. p<0.05; p<0.01 versus control group.